Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Depreciation and Depletion: 2009-2015

Historic Depreciation and Depletion for Lineage Cell Therapeutics (LCTX) over the last 7 years, with Dec 2015 value amounting to $1.1 million.

  • Lineage Cell Therapeutics' Depreciation and Depletion fell 6.06% to $248,000 in Q3 2016 from the same period last year, while for Sep 2016 it was $1.3 million, marking a year-over-year increase of 25.65%. This contributed to the annual value of $1.1 million for FY2015, which is 2.57% up from last year.
  • According to the latest figures from FY2015, Lineage Cell Therapeutics' Depreciation and Depletion is $1.1 million, which was up 2.57% from $1.1 million recorded in FY2014.
  • Lineage Cell Therapeutics' Depreciation and Depletion's 5-year high stood at $1.1 million during FY2015, with a 5-year trough of $373,349 in FY2011.
  • For the 3-year period, Lineage Cell Therapeutics' Depreciation and Depletion averaged around $928,667, with its median value being $1.1 million (2014).
  • Data for Lineage Cell Therapeutics' Depreciation and Depletion shows a peak YoY skyrocketed of 169.26% (in 2011) over the last 5 years.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Depreciation and Depletion stood at $373,349 in 2011, then increased by 3.51% to $386,457 in 2012, then skyrocketed by 70.01% to $657,000 in 2013, then soared by 59.97% to $1.1 million in 2014, then climbed by 2.57% to $1.1 million in 2015.